Instead of trying to destroy glioblastoma cells—a strategy that has delivered limited success for decades—researchers are now exploring whether these deadly cancer cells can be coaxed into a healing-like state. A new study from the Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Kharghar, Navi Mumbai, suggests this approach may be possible.
Resveratrol and Copper Show Biological Impact
The study examined tablets containing resveratrol and copper, two nutraceuticals, and their effects on glioblastoma tumors. Patients consumed the tablets four times a day for an average of 11.6 days before their scheduled tumor-removal surgeries. Researchers then compared their tumors with those from similar patients who did not receive the tablets.
Notably, patients reported no side effects during the treatment period.
Key Biomarker Changes Observed
Tumors exposed to the resveratrol-copper combination showed several promising biological changes. Levels of Ki-67—a marker of rapid cell division—were nearly one-third lower, indicating reduced tumor aggressiveness. Additionally, nine biomarkers known as the “hallmarks of cancer” appeared in 57% fewer cells.
Furthermore, six immune checkpoints that prevent the body from attacking cancer cells fell by 41%. Markers linked to cancer stem cells, which drive tumor spread and treatment resistance, dropped by 56%.
How the Therapy May Work
As reported by Medical News Today, researchers hypothesised that resveratrol and copper generate oxygen radicals that deactivate cell-free chromatin particles released by dying tumor cells. These particles typically worsen tumor behaviour by stimulating surviving cancer cells.
Importantly, the study suggests that resveratrol can shift from acting as an antioxidant to a DNA-damaging agent when paired with copper.
Rethinking Glioblastoma Treatment
Glioblastoma remains one of the most aggressive and treatment-resistant brain cancers, with most patients surviving only 12–18 months despite surgery, radiation, and chemotherapy. Experts say this study supports a growing shift toward modifying cancer behaviour rather than simply killing cells.
The Road Ahead
Although the findings are preliminary and not from a randomized controlled trial, researchers and clinicians agree they open an important new research pathway. Larger trials could determine whether this low-cost, low-toxicity approach can meaningfully change outcomes for patients with glioblastoma.